Stockreport

Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF SGMT's Denifanstat, a first-in-class FASN inhibitor, has multiple applications—acne, MASH, and oncology—offering diversified upside if efficacy is proven across indicat [Read more]